ACADIA Pharmaceuticals Inc. $ACAD Position Lessened by Vanguard Group Inc.

Vanguard Group Inc. lessened its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 0.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,179,371 shares of the biopharmaceutical company’s stock after selling 84,869 shares during the quarter. Vanguard Group Inc. owned approximately 0.09% of ACADIA Pharmaceuticals worth $323,928,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Geneos Wealth Management Inc. boosted its holdings in ACADIA Pharmaceuticals by 113.0% in the third quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 756 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of ACADIA Pharmaceuticals by 107.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 885 shares during the last quarter. USA Financial Formulas acquired a new stake in ACADIA Pharmaceuticals in the 3rd quarter worth approximately $41,000. GAMMA Investing LLC lifted its position in shares of ACADIA Pharmaceuticals by 25.8% during the 3rd quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 690 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in ACADIA Pharmaceuticals by 11.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 534 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Performance

ACAD opened at $24.56 on Friday. The firm’s fifty day moving average is $25.53 and its two-hundred day moving average is $24.45. The firm has a market cap of $4.16 billion, a PE ratio of 10.72, a price-to-earnings-growth ratio of 8.72 and a beta of 0.66. ACADIA Pharmaceuticals Inc. has a twelve month low of $13.40 and a twelve month high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $0.12 by $1.48. The business had revenue of $298.00 million for the quarter, compared to the consensus estimate of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 13.96% and a net margin of 36.49%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.86 EPS. Equities analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.

Key Headlines Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 beat and upgraded 2026 revenue outlook — ACAD reported stronger-than-expected Q4 results (EPS beat) and a milestone year with >$1B in revenue, and guided 2026 revenue to $1.22B–$1.28B, driven by NUPLAZID and DAYBUE. This underpins growth expectations for the company. Acadia Reports Q4 & Full Year 2025 Results
• Positive Sentiment: Analyst price-target upgrades — Several firms raised targets after the quarter (TD Cowen to $37 and Citizens JMP to $35), reflecting confidence in commercial momentum for DAYBUE and NUPLAZID. Benzinga coverage of analyst moves
• Neutral Sentiment: Minor analyst downtick but still constructive — Royal Bank of Canada trimmed its target to $30 but keeps an “outperform” view; this is a modest adjustment rather than a directional reversal. Benzinga: RBC target change
• Neutral Sentiment: Short-interest data appears anomalous — February short-interest entries show 0 shares / NaN increases and 0.0 days-to-cover, indicating a data/reporting glitch rather than a real shift in short positioning.
• Negative Sentiment: Analyst EPS cuts from HC Wainwright — HC Wainwright trimmed Q3 and Q4 2026 EPS estimates (Q3: $0.16 from $0.24; Q4: $0.23 from $0.27), which can pressure near-term expectations despite a buy rating and $37 target.
• Negative Sentiment: Some sell-side caution — Stifel lowered its target to $24 and moved to a “hold,” a more conservative stance that adds selling pressure versus the upgrades. Benzinga: Stifel target change
• Negative Sentiment: Pipeline/regulatory and sales nuances — Coverage noted a sales miss in places and an EU setback for trofinetide that clouds parts of the growth narrative even as core brands accelerate. Zacks: Q4 recap and trofinetide outlook

Analyst Ratings Changes

ACAD has been the topic of several recent research reports. UBS Group lifted their price objective on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Royal Bank Of Canada reduced their price objective on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday. Stifel Nicolaus reduced their price target on shares of ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating on the stock in a research report on Thursday. Mizuho raised shares of ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $29.00 to $35.00 in a research note on Monday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $34.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.74.

Insiders Place Their Bets

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the transaction, the executive vice president directly owned 7,609 shares of the company’s stock, valued at $177,898.42. This trade represents a 47.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 26.50% of the stock is currently owned by company insiders.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.